Investigating rod and cone function in retinal diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the function of rod and cone photoreceptors in individuals with retinal diseases, such as Retinitis Pigmentosa and Stargardt's Disease, as well as in healthy volunteers. Participants aged five and older will undergo various tests, including eye imaging, visual field testing, and electroretinograms, to evaluate their vision under low light conditions. The study seeks to establish normal ranges for dark adaptation kinetics and retinal sensitivity, which could help in detecting and tracking the progression of retinal diseases.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Participant must be five years of age or older.
* Participant (or legal guardian) must understand and sign the protocol s informed consent document.
* Participant must be able to cooperate with the testing required for this study.

For Participants with retinal disease only:

* Participant must have retinal disease, defined as evidence of loss of retinal dysfunction and/or degeneration as established by standard clinical methods including perimetry, ERG and imaging.
* Participant must have a measurable visual acuity.

For Healthy Volunteers only:

-Participant must have visual acuity of 20/20 or better, with or without correction (e.g., glasses or contact lens) in at least one eye.

EXCLUSION CRITERIA:

-Participant with changes in pre-retinal media sufficient to obscure a view of the retina.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Brett G Jeffrey, Ph.D. — National Eye Institute (NEI)
• Study coordinator: Daniel W Claus, R.N.
• Email: daniel.claus@nih.gov
• Phone: (301) 451-1621

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging of outer retinal diseases using adaptive optics

  This study is trying to take detailed pictures of the retina in people with outer retinal diseases to help find better ways to diagnose and understand these conditions.

  Recruiting at 2 sites Food and Drug Administration (FDA) · Bethesda, Maryland and 1 other locations · NCT05355415

• Advanced imaging techniques for eye conditions

  This study is testing new advanced imaging techniques to see if they can help doctors better understand and diagnose eye diseases like retinitis pigmentosa and maculopathy.

  Recruiting Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · Paris · NCT04129021

• Collecting cells to study eye diseases

  This study is collecting hair, skin, and blood samples from people with certain eye diseases to see how these conditions develop and find new treatments.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01432847

• Functional visual field and navigation testing for moderate-to-profound inherited retinal disease

  This project will test whether functional visual field and navigation tests can measure real-world vision and mobility in people with moderate-to-profound inherited retinal diseases.

  Recruiting Ray Therapeutics, Inc. · Irvine, California · NCT07502664

• OCT-980 oral treatment for rhodopsin-associated autosomal dominant retinitis pigmentosa

  This program will test whether the oral drug OCT-980 is safe, well tolerated, and shows signs of benefit in adults with RHO-associated autosomal dominant retinitis pigmentosa and in healthy volunteers.

  Recruiting at 2 sites Phase 1/2 Octant, Inc. · Portland, Oregon and 1 other locations · NCT07408232

• First-in-human, dose-escalation test of AXV-101 for BBS1-related retinal degeneration

  AXV-101 is tested in children and teens with BBS1 retinal degeneration to see if it is safe, find a good dose, and measure how much drug appears in blood, urine, and tears.

  Recruiting Early Phase 1 Axovia Therapeutics · London · NCT07269665

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.